Infinity Pharmaceuticals, Inc.
INFI
INFI was delisted on the 13th of September, 2023.
76 hedge funds and large institutions have $30.8M invested in Infinity Pharmaceuticals, Inc. in 2022 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 10 increasing their positions, 26 reducing their positions, and 15 closing their positions.
334% more call options, than puts
Call options by funds: $482K | Put options by funds: $111K
95% more capital invested
Capital invested by funds: $15.8M → $30.8M (+$15M)
7% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 15
1% less funds holding
Funds holding: 77 → 76 (-1)
62% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.59M |
| 2 |
MIAN
Mariner Independent Advisor Network
Overland Park,
Kansas
|
+$1.35M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
+$907K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$350K |
| 5 |
GC
Gratus Capital
Atlanta,
Georgia
|
+$142K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.11M |
| 2 |
D.E. Shaw & Co
New York
|
-$819K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$455K |
| 4 |
Morgan Stanley
New York
|
-$194K |
| 5 |
Goldman Sachs
New York
|
-$170K |
INFI Hedge Fund Activity: Q3 2022 in Review
76 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Infinity Pharmaceuticals, Inc. (INFI) for Q3 2022, worth a combined $30.8M — up 95% from $15.8M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of INFI and 14 opened new positions — a net loss of 1 holder — while 26 trimmed existing stakes and 10 added.
The largest buyer was Sphera Funds Management, opening a new position worth an estimated $1.59M. The largest seller was Millennium Management, cutting an estimated $1.11M.
- 76 institutional investors held Infinity Pharmaceuticals, Inc. (INFI) as of Q3 2022, down from 77 in Q2 2022.
- Funds reported $30.8M of Infinity Pharmaceuticals, Inc. stock for Q3 2022, up 95% quarter-over-quarter.
- 14 funds opened new Infinity Pharmaceuticals, Inc. positions in Q3 2022 and 15 closed out, a net change of -1 holder.
- The largest Infinity Pharmaceuticals, Inc. buyer in Q3 2022 was Sphera Funds Management, an estimated $1.59M added.
- The largest Infinity Pharmaceuticals, Inc. seller in Q3 2022 was Millennium Management, an estimated $1.11M sold.
Based on aggregated 13F filings for Q3 2022.